Alkermes (ALKS) Non-Current Assets (2011 - 2026)

Alkermes' (ALKS) quarterly Non-Current Assets came in at $2.9 billion in Q1 2026, up 380.89% year-on-year from $602.9 million in Q1 2025, and up 419.77% on a QoQ basis from $557.8 million in Q4 2025.

Alkermes (ALKS) Non-Current Assets (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has 16 years of Non-Current Assets data on file, last reported at $2.9 billion in Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 380.89% year-over-year to $2.9 billion in Q1 2026; TTM through Mar 2026 was $4.7 billion, a 86.59% increase from a year earlier, with the FY2025 full-year figure at $557.8 million, down 12.87% from the prior year.
  • Non-Current Assets for Q1 2026 stood at $2.9 billion, up from $557.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for ALKS reached as high as $2.9 billion in Q1 2026 and fell as low as $557.8 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $851.8 million across 5 years, with a median of $664.7 million in 2024.
  • Across the five-year window, Non-Current Assets declined 27.42% in 2024 and jumped 380.89% in 2026, its largest moves.
  • Year by year, Non-Current Assets stood at $833.7 million in 2022, then decreased by 21.95% to $650.7 million in 2023, then retreated by 1.61% to $640.2 million in 2024, then slipped by 12.87% to $557.8 million in 2025, then soared by 419.77% to $2.9 billion in 2026.
  • Per Business Quant data, the three most recent Non-Current Assets figures were $2.9 billion in Q1 2026, $557.8 million in Q4 2025, and $587.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 36.78 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 26.33 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 8.68 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 79.20 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 3.84 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 15.70 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 25.92 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 2.47 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 9.64 Bn
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn 2.90 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.90 Bn
Dec 31, 2025 557.83 Mn
Sep 30, 2025 587.85 Mn
Jun 30, 2025 617.52 Mn
Mar 31, 2025 602.93 Mn
Dec 31, 2024 640.21 Mn
Sep 30, 2024 591.11 Mn
Jun 30, 2024 664.65 Mn
Mar 31, 2024 655.07 Mn
Dec 31, 2023 650.72 Mn
Sep 30, 2023 814.45 Mn
Jun 30, 2023 789.83 Mn
Mar 31, 2023 812.67 Mn
Dec 31, 2022 833.67 Mn
Sep 30, 2022 888.10 Mn
Jun 30, 2022 911.43 Mn
Mar 31, 2022 963.02 Mn
Dec 31, 2021 962.32 Mn
Sep 30, 2021 942.43 Mn
Jun 30, 2021 899.81 Mn